Polysialic Acids: Potential for Long Circulating Drug, Protein, Liposome and Other Microparticle Constructs

  • Gregory Gregoriadis
  • Ana Fernandes
  • Brenda McCormack
  • Malini Mital
  • Xiaoqin Zhang
Part of the NATO ASI Series book series (NSSA, volume 300)


Optimal use of drugs often requires their extended presence within the vascular system or in extravascular areas (Gregoriadis et al, 1994). For instance, some antibiotics and cytostatics and a variety of peptides and proteins including hormones, cytokines, enzymes, antibodies and haemoglobin (as a blood surrogate) are excreted or removed from the circulation by tissues rapidly and before therapeutic concentrations in target areas can be achieved. Such drugs could be more effective, less toxic and also used in smaller quantities if their presence in the blood circulation (and hence interaction with corresponding receptors or substrates intravascularly or extravascularly) could be prolonged (Lee et al., 1995). In the same way, prolonged circulation of drug delivery systems such as liposomes (Gregoriadis, 1995), other colloidal systems (Davis et al., 1984) and polymers (Domb et al., 1997) would facilitate targeting of drugs to cells other than those (e.g. the reticuloendothelial system; RES) by which many of these systems are normally intercepted (Gregoriadis, 1995; Lee et al., 1995)


Ammonium Sulphate Capsular Polysaccharide Neisseria Meningitidis Polysialic Acid Asparaginase Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Benbough, J.E., Wiblin, C.N., Rafter, T.N.-A., Lee, J., 1979, The effect of chemical modification of L-asparaginase on its persistence in circulating blood of animals, Biochem. Pharmacol. 28:833.PubMedCrossRefGoogle Scholar
  2. Bocci, V., 1987, Metabolism of protein anticancer agents, Pharmacol. Ther. 34:1.PubMedCrossRefGoogle Scholar
  3. Cao, S., Zhao, Q., Ding, Z., Ma, L., Yu, T., Wang, J., Feng, Y., and Cheng, Y., 1990, Chemical modifications of enzyme molecules to improve their characteristics, Ann. New York Acad Sci. 613:460.CrossRefGoogle Scholar
  4. Davis, S.S., Ilium, L., McVie, J.-G., and Tomlison, E., eds., 1984, Microspheres and Drug Therapy, Elsevier, Amsterdam.Google Scholar
  5. Delgado, C., Francis, G.E., and Fister, D., 1992, The uses and properties of PEG-linked proteins, Crit. Rev. Ther. Drug Carrier Syst. 9:249.PubMedGoogle Scholar
  6. Domb, A.J., Kost, J., and Wiseman, D.M., eds., 1997, Handbook of Biodegradable Polymers, Harwood Academic Publishers, Amsterdam.Google Scholar
  7. Fernandes, A., and Gregoriadis, G., 1996, Synthesis, characterization and properties of sialylated catalase, Biochim.Biophys.Acta, 1293:92.CrossRefGoogle Scholar
  8. Fernandes, A., and Gregoriadis, G., 1997, Polysialylated asparaginase: preparation, activity and pharmacokinetics, Biochim.Biophys.Acta, 1341:26.PubMedCrossRefGoogle Scholar
  9. Finne, J., 1982, Occurrence of unique polysialosyl carbohydrate units in glycoproteins of developing brain, J. Biol. Chem. 257:11966.PubMedGoogle Scholar
  10. Gotschlich, E.C., Fraser, B.A., Nischimura, O., Robbins, J.B., and Liu, T.-Y., 1981, Lipid on capsular polysaccharides of gram-negative bacteria, J. Biol. Chem. 256:8915.PubMedGoogle Scholar
  11. Gregoriadis, G., 1995, Engineering liposomes for drug delivery: progress and problems, Trends in Biotechnology, 13:527.PubMedCrossRefGoogle Scholar
  12. Gregoriadis, G., McCormack, B., Wang, Z., and Lifely, R., 1993, Polysialic acids: Potential in drug delivery, FEBS Lett., 315:211.CrossRefGoogle Scholar
  13. Gregoriadis, G., McCormack, B., and Poste, G., eds, 1994, Liposomes in vivo: Control of behaviour, in: Targeting of Drugs: Advances in System Constructs, Plenum, New York.Google Scholar
  14. Haskell, C.M., Canellos, G.P., Leventhal, B.G., Carbone, P.P., and Black, J.B., 1969, L-asparaginase resistance in human leukemia-asparaginase synthetase, Biochem. Pharmacol. 18:2578.PubMedCrossRefGoogle Scholar
  15. Howard, J.B., and Carpentier, F.H., 1972, L-asparaginase from Erwinia carotovora, J. Biol. Chem. 247:10PubMedGoogle Scholar
  16. Keating, M.J., Holmes, R., Lerner, S., Ho, D.H., 1993, L-asparaginase and PEG asparaginas-past, present and future, Leukemia Lymphoma, 10:153.PubMedCrossRefGoogle Scholar
  17. Kravtzoff, R., Ropers, C., Laguerre, M., Muh, J.P., and Chassaigne, M., 1990, Erythrocytes as carriers for L-asparaginase. Methodological, J. Pharm. Pharmacol. 42:473.PubMedCrossRefGoogle Scholar
  18. Lee, V.H.L., Hashida, M., and Mizushina, Y., eds., 1995, Trends and Future Perspectives in Peptide and Protein Drug Delivery, Harwood Academic Publishers, Chur.Google Scholar
  19. Mandrell, R.E., and Zollinger, W.D., 1982, Measurement of antibodies to meningococcal group B polysaccharide: low avidity binding and equilibrium binding constants, J. Immunol. 129:2172.PubMedGoogle Scholar
  20. Moreno, C., Lifely, M.R., and Esdaile, J., 1985, Immunity and protection of mice against Neisseria meningitidis group B by vaccination using polysaccharide complexed with outer membrane proteins: a comparison with purified B polysaccharide, Infect. Immun. 47:527.PubMedGoogle Scholar
  21. Neerunjun, D.E., and Gregoriadis, G., 1976, Tumour regression with liposome-entrapped asparaginase. Some immunological advantages, Biochem. Soc. Trans. 4:133.PubMedGoogle Scholar
  22. Nucci, M.X., Shorr, R., and Abuchowski, A., 1991, The therapeutic value of poly(ethylene-glycol)-modified proteins, Adv. Drug Del. Rev. 6:133.CrossRefGoogle Scholar
  23. Scott, M.D., Lubin, B.H., Zuo, L., and Kuypers, F.A., 1991, Erythocyte defence against hydrogen peroxide: preeminent importance of catalase. J. Lab. Clin. Med. 118:7.PubMedGoogle Scholar
  24. Torchilin, V.P., and Papisov, M.I., 1994, Why do polyethylene glycol-coated liposomes circulate so long?, J. Liposome Res. 4:725.CrossRefGoogle Scholar
  25. Uren, J.R., and Ragin, R.C., 1979, Improvement in the therapeutic, immunological and clearance properties of Escherichia coli and Erwinia carotovora L-asparaginase by attachment of poly-DL-alanyl peptides, Cancer Res. 39:1927.PubMedGoogle Scholar
  26. Yunis, A.A., Arimura, G.K., and Russin, D.J., 1977, Human pancreatic carcinoma (MIA PaCa-2) in continuous culture: sensitivity to asparaginase, Int. J. Cancer, 19:128.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Gregory Gregoriadis
    • 1
  • Ana Fernandes
    • 1
  • Brenda McCormack
    • 1
  • Malini Mital
    • 1
  • Xiaoqin Zhang
    • 1
  1. 1.Centre for Drug Delivery Research, School of PharmacyUniversity of LondonLondonUK

Personalised recommendations